Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 635-644

  Mukhtar, Rita A ^a   Moore, Amy P ^a   Nseyo, Onouwem ^a   Baehner, Frederick L ^a   Au, Alfred ^a   Moore, Dan H ^a   Twomey, Patrick ^a   Campbell, Michael J ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Outcomes disparities; Prognosis; Tumor associated macrophage

Indexed keywords

CYCLINE; HORMONE RECEPTOR; TAMOXIFEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER TISSUE; CARCINOGENESIS; CAUCASIAN; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ETHNICITY; FEMALE; HISPANIC; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; PUBLIC HOSPITAL; RACE; SOCIAL STATUS; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL COUNT; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; UNITED STATES;

EID: 82955163125     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1646-4     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin. doi:10.3322/caac.20073
2. Zaloznik AJ (1995) Breast cancer stage at diagnosis: Caucasians versus Afro-Americans. Breast Cancer Res Treat 34(3):195-198
3. Zaloznik AJ (1997) Breast cancer stage at diagnosis: Caucasians versus Hispanics. Breast Cancer Res Treat 42(2):121-124 (Pubitemid 27056773)
4. Patel TA, Colon-Otero G, Bueno Hume C, Copland JA III, Perez EA (2010) Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist 15(5): 466-475. doi: 10.1634/theoncologist.2010-0004
5. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101(14):984-992. doi:10.1093/jnci/djp175
6. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA (2006) Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24(9):1342-1349. doi: 10.1200/JCO.2005.03.3472 (Pubitemid 46621996)
7. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socio-economic status. Breast Cancer Res Treat 121(2):281-292. doi: 10.1007/s10549-010-0827-x
8. Baquet CR, Mishra SI, Commiskey P, Ellison GL, De Shields M (2008) Breast cancer epidemiology in blacks and whites: dis-parities in incidence, mortality, survival rates and histology. J Natl Med Assoc 100(5):480-488 (Pubitemid 351717360)
9. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100(24):1804-1814. doi:10.1093/jnci/djn411
10. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, De-ming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492-2502. doi:10.1001/jama.295.21.2492 (Pubitemid 43854964)
11. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, Mc Cue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110(4):876-884. doi:10.1002/cncr.22836 (Pubitemid 47257667)
12. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U (2008) Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat 107(3):405-414. doi:10.1007/s10549-007-9560-5 (Pubitemid 351172112)
13. Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG (2008) High prevalence of triple-negative tumors in an urban cancer center. Cancer 113(3):608-615. doi:10.1002/cncr.23569
14. Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG (2008) Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast con-servation therapy for early-stage breast cancer. Cancer 113(9):2565-2574. doi:10.1002/cncr.23881
15. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, Mc Tiernan A, Hubbell FA, Adams-Campbell LL, Prentice R (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439-448. doi:10.1093/jnci/dji064 (Pubitemid 40528607)
16. Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, Byers T (2008) Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol Bio-markers Prev 17(10):2700-2706. doi:10.1158/1055-9965.EPI-08-0504
17. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008) Mac-rophage polarization in tumour progression. Semin Cancer Biol 18(5):349-355. doi:10.1016/j.semcancer.2008.03. 004
18. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Manto-vani A, Sica A (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214(9-10):761-777. doi:10.1016/j.imbio.2009.06.014
19. Hansen BD, Schmidt H, von der Maase H, Sjoegren P, Agger R, Hokland M (2006) Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol 45(4):400-405. doi:10.1080/02841860500471798 (Pubitemid 43884607)
20. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD (2010) Tumor-associated macro-phages and survival in classic Hodgkin's lymphoma. N Engl J Med 362(10):875-885. doi:10.1056/NEJMoa0905680
21. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065-1073. doi: 10.1189/jlb.0609385
22. Siveen KS, Kuttan G (2009) Role of macrophages in tumour progression. Immunol Lett 123(2):97-102. doi:10.1016/j.imlet 2009.02.011
23. Allavena P, Sica A, Solinas G, Porta C, Mantovani A (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66(1):1-9. doi:10.1016/j.critrevonc.2007.07.004 (Pubitemid 351324128)
24. Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. Immunity 23(4):344-346. doi:10.1016/j.immuni. 2005.10.001 (Pubitemid 41443435)
25. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444. doi:10.1038/nature07205
26. Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26(3-4):373-400. doi:10.1007/s10555-007-9072-0 (Pubitemid 350115102)
27. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM (2008) IL-17 expression by breast-cancer-associated mac-rophages: IL-17 promotes invasiveness ofbreast cancer cell lines. Breast Cancer Res 10(6):R95. doi:10.1186/bcr2195
28. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P (2006) Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immuno-biology 211(6-8):487-501. doi:10.1016/j.imbio.2006.06.002
29. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969. doi: 10.1038/nri2448
30. Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87(4):401-406. doi:10.1038/clpt.2009.312
31. Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS (2009) Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 69(24):9498-9506. doi: 10.1158/0008-5472.CAN-09-1868
32. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42(6):717-727. doi:10.1016/j.ejca.2006. 01.003
33. Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miya-zaki M, Ochiai A (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contrib-utes to tumor progression. Int J Cancer 125(6):1276-1284. doi: 10.1002/ijc.24378
34. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, Mc Grath M, Olopade OI, Esserman LJ (2010) Proliferating macrophages associated with high grade, HR negative breast cancer and poor clinical outcome. Breast Cancer Res Treat doi:10.1007/s10549-010-1154-y
35. Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG (2008) Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16(6):513-520. doi:10.1097/PAI.0b013e31818a9d3a
36. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, Weissman AM, Ambs S (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoSOne4(2):e4531. doi:10.1371/journal.pone.0004531
37. Mc Shane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072. doi:10.1200/JCO.2004.01.0454
38. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4(8):e6562. doi:10.1371/journal.pone.0006562
39. Galmbacher K, Heisig M, Hotz C, Wischhusen J, Galmiche A, Bergmann B, Gentschev I, Goebel W, Rapp UR, Fensterle J (2010) Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One 5(3):e9572. doi:10.1371/journal.pone.0009572
40. Steele RJ, Eremin O, Brown M, Hawkins RA (1984) A high macrophage content in human breast cancer is not associated with favourable prognostic factors. Br J Surg 71(6):456-458 (Pubitemid 14116573)
41. Volodko NRA, Rudas M, Jakesz R (1998) Tumour-associated macrophages in breast cancer and their prognostic correlations. The Breast 7(2):99-105 (Pubitemid 28230834)
42. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL (2000) Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190(4):430-436. doi: 10.1002/(SICI)1096-9896(200003)190:4 3.0.CO;2-6 (Pubitemid 30163582)
43. Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79(5-6):991-995. doi:10.1038/sj.bjc.6690158 (Pubitemid 29082138)
44. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angio-genesis and prognosis in invasive breast carcinoma. Cancer Res 56(20):4625-4629 (Pubitemid 26338061)
45. Smith-Bindman R, Miglioretti DL, Lurie N, Abraham L, Barbash RB, Strzelczyk J, Dignan M, Barlow WE, Beasley CM, Ker-likowske K (2006) Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med 144(8):541-553 (Pubitemid 46768143)
46. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE (2009) Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 169(10):1251-1259. doi:10.1093/aje/kwp036
47. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, proges-terone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a popula-tion-based study from the California cancer Registry. Cancer 109(9):1721-1728. doi:10.1002/cncr.22618 (Pubitemid 46668532)
48. Gordon NH (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142(8):796-803
49. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ (2001) Prognostic factors in women with breast cancer: distri-bution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55(5):308-315 (Pubitemid 32336969)
50. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Pankiw-Trost LK, Blattner WA, Hoover RN (1989) The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J Clin Immunol 9(3):214-222 (Pubitemid 19162946)
51. Bain BJ (1996) Ethnic and sex differences in the total and dif-ferential white cell count and platelet count. J Clin Pathol 49(8):664-666 (Pubitemid 26264395)
52. Saxena S, Wong ET (1990) Heterogeneity of common hemato-logic parameters among racial, ethnic, and gender subgroups. Arch Pathol Lab Med 114(7):715-719 (Pubitemid 20207051)
53. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271-285. doi:10.1016/j.canlet.2008.03.018
54. Watkins SK, Li B, Richardson KS, Head K, Egilmez NK, Zeng Q, Suttles J, Stout RD (2009) Rapid release ofcytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur J Immunol 39(8): 2126-2135. doi:10.1002/eji.200839010
55. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, Thun M (2004) Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54(2):78-93 (Pubitemid 38519418)
56. Telli ML, Chang ET, Kurian AW, Keegan TH, Mc Clure LA, Lichtensztajn D, Ford JM, Gomez SL (2010) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. doi:10.1007/s10549-010-1173-8
57. Fong M, Henson DE, Devesa SS, Anderson WF (2006) Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. Breast Cancer Res Treat 97(1):57-65. doi:10.1007/s10549-005-9088-5
58. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010) Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.\-a SEER analysis. BMC Cancer 10:191. doi:10.1186/1471-2407-10- 191
59. Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, Iribarren C, Knowles JW, Li J, Narasimhan B, Sidney S, Southwick A, Myers RM, Quertermous T, Risch N, Tang H (2009) Characterizing the admixed African ancestry of African Americans. Genome Biol 10(12):R141. doi:10.1186/gb-2009-10-12-r141
60. Root M (2003) The use ofrace in medicine as a proxy for genetic differences. Philos Sci 70(5):1173-1183 (Pubitemid 38492064)
61. Moldovan GL, Pfander B, Jentsch S (2007) PCNA, the maestro of the replication fork. Cell 129(4):665-679. doi:10.1016/j.cell. 2007.05.003 (Pubitemid 46802385)
62. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, Mc Intush EW, Li LY, Hawke DH, Kobayashi R, Hung MC (2006) Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 8(12):1359-1368. doi: 10.1038/ncb1501 (Pubitemid 44835110)
63. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605-612. doi:10.1158/0008-5472.CAN-05- 4005 (Pubitemid 43165918)
64. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S, Naylor S (2000) The macro-phage\-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 7(3):255-262. doi:10.1038/sj.gt.3301058 (Pubitemid 30113775)
65. Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, Alvarez X, Kuroda MJ, Williams KC (2010) Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma. PLoS Pathog 6(4):e1000842. doi:10.1371/journal.ppat.1000842
66. Williams K, Schwartz A, Corey S, Orandle M, Kennedy W, Thompson B, Alvarez X, Brown C, Gartner S, Lackner A (2002) Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am J Pathol 161(2):575-585. doi:10.1016/S0002-9440(10)64213-7 (Pubitemid 36142166)
67. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC (1995) Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 48(3):753-760
68. Dijkstra CD, Dopp EA, Joling P, Kraal G (1985) The heteroge-neity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54(3):589-599 (Pubitemid 15132717)
69. Aziz A, Soucie E, Sarrazin S, Sieweke MH (2009) Maf B/c-Maf deficiency enables self-renewal of differentiated functional macrophages. Science 326(5954):867-871. doi:10.1126/science. 1176056
70. Watlington AT, Byers T, Mouchawar J, Sauaia A, Ellis J (2007) Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer? Cancer 109(10):2093-2099. doi:10.1002/cncr.22640 (Pubitemid 46744205)
71. Wojcik BE, Spinks MK, Stein CR (2003) Effects of screening mammography on the comparative survival rates of African American, white, and Hispanic beneficiaries of a comprehensive health care system. Breast J 9(3):175-183 (Pubitemid 36627162)
72. Rayson D, Payne JI, Abdolell M, Barnes PJ, Mac Intosh RF, Foley T, Younis T, Burns A, Caines J (2011) Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer 11(1):27-32. doi:10.3816/CBC.2011.n.005
73. Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, Kup-pusamy P, Marsh CB (2009) Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macro-phages. Cancer Res 69(5):2133-2140. doi:10.1158/0008-5472. CAN-08-1405